Home
/

Is High Testosterone Good?

Bill Maish, MD
Clinical Product Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

Higher testosterone is beneficial up to a point, but the relationship is not linear. In men, supraphysiological levels are associated with reduced HDL cholesterol, left ventricular hypertrophy, and erythrocytosis, with hematocrit monitoring recommended when values exceed 54%. In women, elevated testosterone is most commonly linked to PCOS, affecting 8 to 13 percent of reproductive-age women. Optimal levels are always context-dependent.

Read more →
Table of contents
```html

Whether high testosterone is actually a good thing

Higher testosterone is associated with meaningful benefits — but only within the physiological range. The evidence for benefits relates to moving from deficient to normal, not from normal to supraphysiological. Beyond the normal reference range, the dose-response curve bends, and the risks outweigh the incremental gains.

In men who are not using exogenous testosterone or anabolic steroids, levels substantially above the upper limit of the reference range are relatively uncommon and warrant investigation. Possible causes include testosterone-secreting testicular or adrenal tumors (rare), congenital adrenal hyperplasia, and assay interference. In practice, the most common context for above-range testosterone in men is deliberate exogenous administration through testosterone replacement therapy (TRT) or performance-enhancing use, where dose management is key. This is also distinct from the transient, physiologic elevations seen with resistance training — for more on that distinction, see does lifting weights increase testosterone.

Women produce and require testosterone at lower concentrations than men. Androgens in women support muscle mass, libido, bone density, and energy. However, testosterone levels substantially above the female reference range are most commonly associated with polycystic ovary syndrome (PCOS), a condition affecting 8–13% of women of reproductive age characterized by ovarian androgen excess, irregular cycles, and often insulin resistance. Elevated testosterone in women may also result from congenital adrenal hyperplasia, adrenal or ovarian tumors, or exogenous androgen administration. SHBG levels are particularly relevant in women, as low SHBG increases androgen bioavailability and worsens androgen excess symptoms.

How testosterone behaves above the normal range

Supraphysiological testosterone — levels substantially above the reference range — affects multiple physiological systems in ways that diverge from the benefits seen at normal concentrations. The most clinically significant mechanism is erythropoiesis: testosterone stimulates red blood cell production, and at high doses or supraphysiological levels this can produce polycythemia, raising blood viscosity and the risk of thrombotic events including stroke and deep vein thrombosis. Hematocrit monitoring is standard practice for men on testosterone therapy, with providers typically reducing dose or holding therapy when hematocrit rises above 54%.

Supraphysiological testosterone is also associated with dyslipidemia — particularly reductions in HDL cholesterol — and left ventricular hypertrophy. A 2024 Annals of Internal Medicine meta-analysis demonstrates that while low testosterone increases cardiovascular mortality risk, the relationship between testosterone and cardiovascular outcomes is not linear, and supraphysiological levels introduce distinct risks. These cardiovascular effects are separate from, and additive to, the erythrocytosis risk.

In women, the primary mechanism of androgen excess in PCOS is ovarian overproduction of androgens, closely linked to insulin resistance. Elevated insulin stimulates ovarian androgen synthesis and suppresses hepatic SHBG production, which in turn increases the bioavailability of already-elevated testosterone — a compounding effect that explains why metabolic context is inseparable from hormonal interpretation in this population.

How far above range starts to matter

The evidence is clearest for men with documented hypogonadism: restoring testosterone to the low-to-normal range is associated with improved bone density, muscle mass, mood, metabolic markers, and, in some studies, reduced cardiovascular event risk. A European Heart Journal study found that normalizing testosterone levels in hypogonadal men was associated with significantly reduced incidence of myocardial infarction and all-cause mortality.

The key phrase is "normalizing to the reference range." The benefits documented in hypogonadism studies relate to moving from deficient to adequate, not from adequate to supraphysiological. The evidence base for benefits of testosterone levels beyond the upper reference limit in men without deficiency is substantially weaker and associated with increasing risk. The 2024 Annals meta-analysis reinforces this: cardiovascular mortality is raised at low testosterone, but supraphysiological levels introduce a distinct and separate risk profile — the curve does not simply plateau, it reverses.

Research on outcomes including cardiovascular risk, bone density, metabolic health, and mortality generally identifies the mid-to-upper normal range as associated with the best outcomes. The Endocrine Society clinical guideline and the 2024 Annals meta-analysis both suggest that levels in the normal physiological range, rather than above it, represent the healthiest target for most men. What constitutes the optimal range for a given individual depends on age, health status, and clinical context.

Why high testosterone hits two people differently

A total testosterone reading in the "high" range means different things depending on SHBG, hematocrit, and metabolic state. The markers below explain why the same number can represent optimal health in one person and a clinical concern in another.

  • Total testosterone: The standard first-line number — but total alone is incomplete without knowing how much is biologically active.
  • Free testosterone: The biologically active fraction; a high total can coexist with low free if SHBG is elevated — or amplify risk if SHBG is low.
  • SHBG: Determines how much total testosterone is actually bioavailable; low SHBG makes the same total testosterone more androgenically potent and carries higher risk of androgen-excess symptoms. A man with high total testosterone but also high SHBG may have relatively little bioavailable testosterone despite the elevated total.
  • Hematocrit: Testosterone stimulates red blood cell production; a rising hematocrit (threshold: 54%) is the primary safety monitoring marker for elevated or exogenous testosterone.
  • hs-CRP: Low testosterone is associated with elevated CRP; conversely, elevated testosterone is associated with HDL reduction — both affect vascular inflammation differently.
  • Fasting glucose + insulin: Insulin resistance is closely linked to testosterone in both sexes (PCOS in women; low T in insulin-resistant men); metabolic context is essential for interpreting hormonal findings.
  • Bioavailable testosterone: Directly measured fraction (not SHBG-estimated); the 2018 Endocrine Society guideline recommends this when SHBG abnormalities are suspected.

Signals that high testosterone has gone too far

Most people asking whether high testosterone is beneficial are operating within or near the physiological range, where these signals are unlikely to appear. They become relevant when levels are substantially above range — whether from exogenous use, an underlying condition, or a combination of factors.

In men, the signals worth noting include new-onset oily skin and acne in a previously clear adult, mood lability, irritability, or aggression during a period of elevated or exogenous testosterone, and hematocrit rising above 54% — the threshold at which erythrocytosis becomes a clinical concern. While testosterone in the normal range is associated with positive mood and reduced anxiety, supraphysiological levels have been associated with mood instability in some individuals; the relationship is individual and not deterministic, but it is a recognized clinical consideration.

In women, the relevant signals are irregular or absent menstrual cycles, hirsutism (excess body and facial hair), acne, and scalp hair thinning — the classic presentation of androgen excess associated with PCOS or other androgen-producing conditions. These symptoms reflect both the absolute level of testosterone and its bioavailability, which is why SHBG is an essential part of the picture.

Why more testosterone isn't automatically better

Testosterone in the mid-to-upper normal range is associated with the best outcomes. Above the reference range, the dose-response curve changes direction. This is the finding that "high testosterone is good" content on the internet most consistently misses: the studies showing benefits are almost entirely studies of hypogonadism correction, not studies of supraphysiological elevation.

Above the reference range, the cardiovascular risk profile shifts. HDL cholesterol falls, left ventricular hypertrophy becomes a concern, and erythrocytosis — with its attendant thrombosis risk — begins to accumulate. Androgenetic alopecia accelerates in genetically susceptible individuals through the DHT pathway: testosterone is converted by 5-alpha-reductase to dihydrotestosterone, a more potent androgen, and higher testosterone provides more substrate for that conversion. None of these effects are present at physiological levels; they emerge specifically in the supraphysiological range. For context on how exercise-induced testosterone elevations differ from pathological or exogenous elevation, see does sprinting increase testosterone.

There is also an important SHBG nuance that cuts in both directions. A "high" total testosterone reading may mean relatively little if SHBG is also high — much of that testosterone is bound and inactive. Conversely, a total testosterone reading that appears normal can carry amplified androgenic risk if SHBG is low, because a greater proportion is free and biologically active. The number alone does not tell the full story, and chasing a higher total without accounting for SHBG can produce a misleading picture of where someone actually sits on the dose-response curve.

When elevated testosterone needs a clinician's read

If symptoms of androgen excess (in women) or supraphysiological elevation (in men) are present, that is a clinical evaluation — the cause matters as much as the number. An above-range result without symptoms is still worth discussing with a provider, because the trend over time and the underlying cause determine appropriate next steps.

Understanding what your testosterone level actually means in context is the foundation of Superpower's approach to preventive health.

```

FAQs

Most laboratories set the upper limit of the normal male reference range for total testosterone at approximately 900 to 1,000 ng/dL. Levels consistently above this threshold are considered supraphysiological and warrant clinical evaluation for cause. There is no single threshold at which elevated testosterone becomes definitively harmful, but risk increases progressively with the degree and duration of elevation above the normal range.
Supraphysiological testosterone is associated with reduced HDL cholesterol, left ventricular hypertrophy, and increased red blood cell production (erythrocytosis), which raises blood viscosity and thrombosis risk. A 2024 Annals of Internal Medicine meta-analysis confirmed that while low testosterone raises cardiovascular mortality risk, the relationship is not linear and supraphysiological levels introduce distinct cardiovascular risks. Benefits from testosterone are associated with restoring deficient levels to the normal range, not exceeding it.
Elevated testosterone in women most commonly results from polycystic ovary syndrome (PCOS), which affects 8 to 13% of women of reproductive age and involves ovarian androgen excess often accompanied by insulin resistance. Other causes include congenital adrenal hyperplasia, adrenal or ovarian tumors, and exogenous androgen administration. Low SHBG increases androgen bioavailability and can worsen androgen excess symptoms even when total testosterone is only modestly elevated.
Androgen excess in women may be associated with irregular or absent menstrual cycles, hirsutism (excess facial and body hair), acne, and scalp hair thinning (androgenetic alopecia). These symptoms are most commonly linked to PCOS but can reflect other androgen-secreting conditions. Testing total testosterone, free testosterone, and SHBG together provides the most complete picture of androgen status.
Androgenetic alopecia is driven by dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha-reductase. Elevated testosterone provides more substrate for DHT production in genetically susceptible individuals, which is why scalp hair thinning is more common in people with high androgen levels. Women with elevated testosterone are also more likely to experience this pattern alongside other androgen excess signs.
No. The benefits of testosterone for men are associated with restoring deficient levels to the normal physiological range, not exceeding it. Research on outcomes including cardiovascular risk, bone density, and mortality consistently identifies the mid-to-upper normal range as optimal. The evidence base for benefits above the reference range is weak, and supraphysiological levels are associated with cardiovascular, hematological, and mood risks.

References

  1. Yeap, B. B., Marriott, R. J., Dwivedi, G., Adams, R. J., Antonio, L., Ballantyne, C. M., Bauer, D. C., Bhasin, S., Biggs, M. L., Cawthon, P. M., Couper, D. J., Dobs, A. S., Flicker, L., Handelsman, D. J., Hankey, G. J., Hannemann, A., Haring, R., Hsu, B., Martin, S. A., ... Murray, K. (2024). Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses. Annals of internal medicine, 177(6), 768-781. https://doi.org/10.7326/M23-2781
  2. Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 103(5), 1715-1744. https://doi.org/10.1210/jc.2018-00229
  3. Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Ambrose, J. A., & Barua, R. S. (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European heart journal, 36(40), 2706-15. https://doi.org/10.1093/eurheartj/ehv346
  4. Deswal, R., Narwal, V., Dang, A., & Pundir, C. S. (2020). The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of human reproductive sciences, 13(4), 261-271. https://doi.org/10.4103/jhrs.JHRS_95_18
  5. Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., Connor Westfall, J., Bae, H., Gordeuk, V., & Bhasin, S. (2014). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. The journals of gerontology. Series A, Biological sciences and medical sciences, 69(6), 725-35. https://doi.org/10.1093/gerona/glt154

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey